Debt-to-equity in % of Chemomab Therapeutics Ltd. from Q3 2020 to Q2 2023

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Chemomab Therapeutics Ltd. quarterly Debt-to-equity history and change rate from Q3 2020 to Q2 2023.
Chemomab Therapeutics Ltd. Debt-to-equity for the quarter ending 30 Jun 2023 was 20.2 %, a 264% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Chemomab Therapeutics Ltd. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q2 2023	20.2	+14.6	+264%	30 Jun 2023
Q1 2023	15	+10.6	+243%	31 Mar 2023
Q4 2022	10.9	+6	+123%	31 Dec 2022
Q3 2022	7.78	+2.25	+40.7%	30 Sep 2022
Q2 2022	5.54	-2.29	-29.2%	30 Jun 2022
Q1 2022	4.37	-7.55	-63.4%	31 Mar 2022
Q4 2021	4.9	-15.5	-76%	31 Dec 2021
Q3 2021	5.53	-20.8	-79%	30 Sep 2021
Q2 2021	7.83			30 Jun 2021
Q1 2021	11.9			31 Mar 2021
Q4 2020	20.4			31 Dec 2020
Q3 2020	26.4			30 Sep 2020

* An asterisk sign (*) next to the value indicates that the value is likely invalid.